Form 4: Agenus CEO Garo Armen Opts for Stock Salary

Agenus Inc. CEO Garo H. Armen received 3,734 shares of common stock as salary for the pay period ending September 19, 2025, demonstrating equity-based compensation.

Summary

• Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc., acquired 3,734 shares of common stock.
• This acquisition was in lieu of cash salary for the pay period ending September 19, 2025, at his request and with the approval of the Agenus Inc. Compensation Committee.
• The shares were issued at a price of $4.38 per share, which was the closing price on September 19, 2025.
• The shares are fully vested on the date of issuance and were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan.
• Following this transaction, Garo H. Armen directly beneficially owns 278,442 shares of common stock.
• Indirect beneficial ownership includes 31,298 shares held in Dr. Armen's IRA accounts and 28,950 shares held by the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where Dr. Armen has investment authority or a pecuniary interest.

Sentiment

Score: 7

Explanation: The decision by the CEO to take salary in stock instead of cash is a positive signal, indicating strong alignment with shareholder interests and confidence in the company's long-term value. It's a routine compensation event, so the impact is moderately positive rather than highly transformative.

Positives

• Management's decision to take salary in stock aligns their interests with those of shareholders, indicating confidence in the company's future performance.
• The shares are fully vested upon issuance, providing immediate equity ownership.

Negatives

• No specific negatives are identified in this routine insider transaction report.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

NA

Management Comments

• Garo H. Armen's salary is being paid in stock, in lieu of cash, at his request and with the approval of the Agenus Inc. Compensation Committee.

Industry Context

Insider stock acquisitions, particularly by senior executives, are generally viewed positively as they signal management's confidence in the company's prospects and align their financial interests with those of shareholders. This practice is common in the biotechnology sector, where long-term value creation is a key focus.

Stakeholder Impact

• Shareholders: Increased alignment of CEO's financial interests with shareholders, potentially fostering greater confidence.
• Employees: May signal management's belief in the company's stability and future growth, potentially boosting morale.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the CEO opted to receive salary in stock. While this demonstrates management's alignment with shareholder interests and confidence in the company, it does not present new fundamental information or significant operational changes that would warrant a change in investment recommendation. The transaction itself is not a catalyst for a 'buy' or 'sell' decision, thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Agenus, AGEN, Form 4, Insider Transaction, Stock Compensation, Garo Armen, Equity Incentive Plan, CEO Compensation